SYMBOL:

    Up to 100 tickers separated by a space .....Watch Post-Market activities
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
PUMA BIOTECHNOLOGY INC
(NYSE:PBYI Last Sale: 10.34 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details


NYSE: (PBYI : $10.34)
$402,857 million Market Cap at Market Close, July 1, 2022
Biomedics SubIndustry up .00% / Health Industry up .00% Today
10880 Wilshire Boulevard, Suite 2150 Research Report Earnings Snapshot - Last 11/10/18
Los Angeles, 90024 Fact Sheet
Phone: (424) 248-6500 Financial Statements
Peer Comparison

Alan H. Auerbach, Pres./CEO, Charles R. Eyler, CFO
Focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer. Transfer from OTCBB to NYSE October 19, 2012 after raising $129.1 million in a 8.625 million share offering at $16 led by Merrill Lynch and Leerink Swann.
Historical Charts    Technical Analysis
No Historical Data available for PBYI

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common PBYI $10.34 $10.34 0 .0 $9.07 $10.37 1,045,009 $9.07 $10.37 38,960,995
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10126
Common Stock $402,856,688

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2025 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex